Condition: Biliary Tract Cancer · Sponsor: Jazz Pharmaceuticals
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@JazzPharma.com
Always discuss trial participation with your own doctor first.
| City of Hope(City of Hope National Medical Center, City of Hope Medical Center) | Duarte, California, United States | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Lone Tree, Colorado, United States | Withdrawn |
| AdventHealth Hematology and Oncology | Orlando, Florida, United States | Recruiting |
| Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| The University of Kansas Cancer Center - Westwood | Westwood, Kansas, United States | Withdrawn |
| Norton Cancer Institute - Audubon | Louisville, Kentucky, United States | Recruiting |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Active Not Recruiting |
| University of Michigan Hospital | Ann Arbor, Michigan, United States | Recruiting |
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| Minnesota Oncology Hematology, P.A. | Maple Grove, Minnesota, United States | Active Not Recruiting |
| Atlantic Health System/Morristown Medical Center | Morristown, New Jersey, United States | Active Not Recruiting |
+ 173 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06282575